PFIZER - Pfizer

📊 NSE: PFIZER 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 10:58

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment, 'Pharmaceuticals'. In Q1 2020-21, Internal Medicine grew 13%, while Vaccines declined 23% and Hospital revenue fell 41%. Overall revenue for Q1 2020-21 was INR 515 Cr, a decline of 5.3% YoY from INR 544 Cr.

Geographic Revenue Split

Not disclosed in available documents, though the company operates primarily in India with service revenue of INR 10 Cr from Pfizer Inc. affiliates.

Profitability Margins

For FY 2025, Net Profit Margin was 33.65% (up from 25.14% in FY 2024) and Operating Profit Margin was 29.78% (up from 26.13% YoY). Q1 2020-21 Gross Margin was 65% (INR 327 Cr) vs 64% YoY.

EBITDA Margin

Operating Profit Margin for FY 2025 stood at 29.78%, representing a 13.9% YoY improvement from 26.13%. Q1 2020-21 profit from operations was INR 159 Cr, a 13% growth YoY.

Capital Expenditure

Not explicitly disclosed, but the company realized a net gain of INR 172.81 Cr from the sale of leasehold rights and buildings at Thane to Zoetis in FY 2025.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported N.A. for debt-equity and interest coverage ratios, indicating a debt-free status.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents, though COGS (Cost of Materials Consumed and Purchases of Stock-in-Trade) represents approximately 35% of sales based on a 65% gross margin.

Key Suppliers

Pfizer Inc. affiliates provide services and likely product supply to Pfizer Limited.

Raw Material Costs

Cost of materials and stock-in-trade purchases represent approximately 35% of revenue (INR 176 Cr in Q1 2020-21). Procurement is influenced by product mix and global affiliate sourcing.

Logistics & Distribution

Freight and forwarding charges decreased in Q1 2020-21 due to lower sales volumes and movement restrictions.

📈 Strategic Growth

Expected Growth Rate

0.8-2%

Growth Strategy

Growth is driven by a three-pronged strategy: a specialty focus leveraging science, customized go-to-market solutions (hybrid FTE/contract models), and maximizing the share of the global product portfolio, which increased from 36.3% in 2016 to 48.6% in 2020.

Products & Services

Pediatric vaccines, Internal Medicine drugs (legacy brands), Oncology treatments, and Hospital-based specialty therapies.

Brand Portfolio

Upjohn (divesting), Consumer Healthcare (divesting), and Pfizer Global Portfolio products.

New Products/Services

The company is considering several new products from its patented global basket to drive future revenue contribution.

Market Expansion

Expansion of distribution and coverage through a hybrid sales model and increased 'feet on the ground' in targeted territories.

Market Share & Ranking

Pfizer Limited reported 3.9% growth (MAT June 2020) compared to MNC industry growth of 3.7%.

Strategic Alliances

Divestment of Thane assets to Zoetis for INR 172.81 Cr and ongoing service agreements with Pfizer Inc. affiliates.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and specialty portfolios; recovery was expected in 2021 following a 4.9% industry contraction in early 2020.

Competitive Landscape

MNCs grew at 3.7% vs Indian companies at 7.7% (MAT June 2020), indicating higher competition from local generic players.

Competitive Moat

Durable moat through a 70-year brand presence in India and a growing share of global patented products (48.6% of sales), which are harder to replicate than generics.